Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(21)01443-4 ◽

2021 ◽

Author(s):

Bernhard Ludvik ◽

Francesco Giorgino ◽

Esteban Jódar ◽

Juan P Frias ◽

Laura Fernández Landó ◽

...

Keyword(s):

Type 2 Diabetes ◽

Sglt2 Inhibitors ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Once Daily ◽

Daily Insulin ◽

Parallel Group

Download Full-text

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

Diabetes Care ◽

10.2337/dc12-1668 ◽

2013 ◽

Vol 36 (4) ◽

pp. 858-864 ◽

Cited By ~ 148

Author(s):

L. Meneghini ◽

S. L. Atkin ◽

S. C. L. Gough ◽

I. Raz ◽

L. Blonde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Target Trial ◽

Open Label ◽

Once Daily ◽

Parallel Group ◽

Dosing Intervals

Download Full-text

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(17)30085-2 ◽

2017 ◽

Vol 5 (5) ◽

pp. 355-366 ◽

Cited By ~ 116

Author(s):

Vanita R Aroda ◽

Stephen C Bain ◽

Bertrand Cariou ◽

Milivoj Piletič ◽

Ludger Rose ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Parallel Group

Download Full-text

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.13856 ◽

2019 ◽

Vol 21 (12) ◽

pp. 2674-2683 ◽

Cited By ~ 4

Author(s):

Kohei Kaku ◽

Eiichi Araki ◽

Yukio Tanizawa ◽

Bue Ross Agner ◽

Tomoyuki Nishida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomized Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy

Download Full-text

Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in J apanese patients with type 2 diabetes: a randomized, open‐label, phase III , non‐inferiority study

Diabetes Obesity and Metabolism ◽

10.1111/dom.12540 ◽

2015 ◽

Vol 17 (10) ◽

pp. 994-1002 ◽

Cited By ~ 50

Author(s):

E. Araki ◽

N. Inagaki ◽

Y. Tanizawa ◽

T. Oura ◽

M. Takeuchi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Daily Insulin ◽

Open Label Phase

Download Full-text

Author response for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/response1 ◽

2019 ◽

Author(s):

Kohei Kaku ◽

Eiichi Araki ◽

Yukio Tanizawa ◽

Bue Ross Agner ◽

Tomoyuki Nishida ◽

...

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Author Response ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v1/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/review3 ◽

2019 ◽

Author(s):

Yoshifumi Saisho

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Review for "Superior efficacy with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese subjects with type 2 diabetes in a phase 3, open‐label, randomised trial"

10.1111/dom.13856/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Randomised Trial ◽

Fixed Ratio ◽

Insulin Degludec ◽

Open Label ◽

Phase 3 ◽

Superior Efficacy ◽

Japanese Subjects

Download Full-text

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(14)70174-3 ◽

2014 ◽

Vol 2 (11) ◽

pp. 885-893 ◽

Cited By ~ 185

Author(s):

Stephen C L Gough ◽

Bruce Bode ◽

Vincent Woo ◽

Helena W Rodbard ◽

Sultan Linjawi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Fixed Ratio ◽

Insulin Degludec ◽

Treat To Target ◽

Efficacy And Safety ◽

Target Trial ◽

Open Label ◽

Phase 3

Download Full-text

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2012.07.007 ◽

2012 ◽

Vol 34 (9) ◽

pp. 1892-1908.e1 ◽

Cited By ~ 53

Author(s):

Nobuya Inagaki ◽

Yoshihito Atsumi ◽

Tomonori Oura ◽

Hitoshi Saito ◽

Takeshi Imaoka

Keyword(s):

Type 2 Diabetes ◽

Safety Profile ◽

Japanese Patients ◽

Efficacy And Safety ◽

Open Label ◽

Once Daily ◽

Parallel Group

Download Full-text